“…The experience with dapsone as an agent for PCP prophylaxis in HIV-infected patients has been increasing over recent years. Dapsone has been tested as an agent for PCP prophylaxis at different dosage regimens, namely, 50 to 100 mg daily (4,16,18,22), 100 mg twice or thrice weekly (6,7,29,31), and 100, 200, or 300 mg once weekly (1,11,17,21,25,27). Even though the comparability of these investigations is hindered by such variables as disease stage at study entry, duration of follow-up, concomitant anti-HIV therapy, primary versus secondary prophylaxis, and risk factor, it appears that a daily dosage may be more effective but may be associated with higher rates of adverse reactions than weekly dosage regimens, while weekly regimens may be associated with lower rates of adverse effects and a higher incidence of treatment failures than daily regimens.…”